120 related articles for article (PubMed ID: 27912079)
1. A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy.
Hu S; Neff CP; Kumar DM; Habu Y; Akkina SR; Seki T; Akkina R
Virology; 2017 Jan; 501():115-118. PubMed ID: 27912079
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Bollen P; Reiss P; Schapiro J; Burger D
Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
[TBL] [Abstract][Full Text] [Related]
3. Triumeq--a 3-drug combination for HIV.
Med Lett Drugs Ther; 2015 Jan; 57(1459):7-8. PubMed ID: 25555073
[No Abstract] [Full Text] [Related]
4. Real-world evaluation of the safety and tolerability of abacavir/dolutegravir/lamivudine in an incarcerated population.
Brizzi MB; Chiampas TD; Michienzi SM; Young JD; Patel MC; Badowski ME
Int J STD AIDS; 2019 Oct; 30(12):1163-1168. PubMed ID: 31558124
[No Abstract] [Full Text] [Related]
5. Abacavir + dolutegravir + lamivudine for the treatment of HIV.
Comi L; Maggiolo F
Expert Opin Pharmacother; 2016 Oct; 17(15):2097-106. PubMed ID: 27616133
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters.
Bossacoma Busquets F; Noguera-Julian A; Sanchez E; Fortuny C
J Antimicrob Chemother; 2017 Oct; 72(10):2958-2960. PubMed ID: 29091219
[No Abstract] [Full Text] [Related]
7. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
8. The preclinical discovery and development of dolutegravir for the treatment of HIV.
Bailly F; Cotelle P
Expert Opin Drug Discov; 2015; 10(11):1243-53. PubMed ID: 26517818
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model.
Berges BK; Wheat WH; Palmer BE; Connick E; Akkina R
Retrovirology; 2006 Nov; 3():76. PubMed ID: 17078891
[TBL] [Abstract][Full Text] [Related]
10. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
[TBL] [Abstract][Full Text] [Related]
11. Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject.
Rossotti R; Maggioni M; Merli M; Orcese C; Iavarone M; Puoti M
AIDS; 2018 Jul; 32(12):1727-1729. PubMed ID: 30001246
[No Abstract] [Full Text] [Related]
12. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
14. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.
Anderson AM; Bartlett JA
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):871-83. PubMed ID: 16307500
[TBL] [Abstract][Full Text] [Related]
15. Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis.
Moore SE; Huesgen E; Howe Z
Int J STD AIDS; 2020 Mar; 31(3):285-287. PubMed ID: 32036755
[No Abstract] [Full Text] [Related]
16. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
[TBL] [Abstract][Full Text] [Related]
17. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
[TBL] [Abstract][Full Text] [Related]
18. A NEW TRIPLE THREAT AGAINST THE VIRUS.
Vázquez E
Posit Aware; 2014; 26(7):37-9. PubMed ID: 26292381
[No Abstract] [Full Text] [Related]
19. Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment.
Cattaneo D; Capetti A; Rizzardini G
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):245-252. PubMed ID: 30704313
[TBL] [Abstract][Full Text] [Related]
20. Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection.
Senanayake TH; Gorantla S; Makarov E; Lu Y; Warren G; Vinogradov SV
Mol Pharm; 2015 Dec; 12(12):4226-36. PubMed ID: 26565115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
